A detailed history of Tower Research Capital LLC (Trc) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,844 shares of TARS stock, worth $193,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,844
Previous 342 1608.77%
Holding current value
$193,728
Previous $12,000 1216.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.17 - $38.73 $138,485 - $213,092
5,502 Added 1608.77%
5,844 $158,000
Q1 2024

May 15, 2024

SELL
$19.61 - $39.22 $82,714 - $165,429
-4,218 Reduced 92.5%
342 $12,000
Q4 2023

Feb 13, 2024

BUY
$12.98 - $20.73 $10,695 - $17,081
824 Added 22.06%
4,560 $92,000
Q3 2023

Nov 14, 2023

BUY
$14.75 - $24.62 $41,668 - $69,551
2,825 Added 310.1%
3,736 $66,000
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $485 - $824
42 Added 4.83%
911 $16,000
Q1 2023

May 09, 2023

BUY
$11.92 - $16.27 $1,513 - $2,066
127 Added 17.12%
869 $11,000
Q4 2022

Feb 10, 2023

SELL
$14.12 - $18.72 $10,561 - $14,002
-748 Reduced 50.2%
742 $11,000
Q3 2022

Nov 10, 2022

SELL
$14.08 - $18.5 $16,065 - $21,108
-1,141 Reduced 43.37%
1,490 $26,000
Q2 2022

Aug 15, 2022

SELL
$11.08 - $19.08 $42,026 - $72,370
-3,793 Reduced 59.04%
2,631 $38,000
Q1 2022

May 12, 2022

BUY
$14.49 - $24.28 $83,636 - $140,144
5,772 Added 885.28%
6,424 $108,000
Q4 2021

Feb 14, 2022

BUY
$21.21 - $29.68 $3,966 - $5,550
187 Added 40.22%
652 $14,000
Q3 2021

Nov 15, 2021

SELL
$21.45 - $29.22 $15,186 - $20,687
-708 Reduced 60.36%
465 $10,000
Q2 2021

Aug 16, 2021

BUY
$27.16 - $38.59 $21,890 - $31,103
806 Added 219.62%
1,173 $34,000
Q1 2021

May 17, 2021

SELL
$27.37 - $47.25 $7,608 - $13,135
-278 Reduced 43.1%
367 $12,000
Q4 2020

Feb 16, 2021

BUY
$19.17 - $49.62 $12,364 - $32,004
645 New
645 $27,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $884M
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.